{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+match+Add-back",
    "query": {
      "intervention": "Placebo to match Add-back"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+match+Add-back&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-09T12:31:54.371Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00973024",
      "title": "A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Low Back Pain",
        "Low Back Pain, Recurrent"
      ],
      "interventions": [
        {
          "name": "JNJ-42160443 3 mg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-42160443 1 mg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-42160443 6 mg/3mg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-42160443 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 389,
      "start_date": "2009-09",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2016-06-06",
      "last_synced_at": "2026-09-09T12:31:54.371Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Pismo Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00973024"
    },
    {
      "nct_id": "NCT03070899",
      "title": "Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uterine Fibroids",
        "Heavy Menstrual Bleeding"
      ],
      "interventions": [
        {
          "name": "OBE2109",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match OBE2109",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match Add-back",
          "type": "DRUG"
        },
        {
          "name": "Add-back",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ObsEva SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 526,
      "start_date": "2017-04-20",
      "completion_date": "2021-04-12",
      "has_results": false,
      "last_update_posted_date": "2021-06-09",
      "last_synced_at": "2026-09-09T12:31:54.371Z",
      "location_count": 116,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 93 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Vestavia Hills",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03070899"
    },
    {
      "nct_id": "NCT03986944",
      "title": "A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "75 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "200 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "Add-back capsule (E2 1 mg / NETA 0.5 mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet to match 75 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet to match 200 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsule to match Add-back capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kissei Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 85,
      "start_date": "2019-05-23",
      "completion_date": "2021-02-16",
      "has_results": true,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-09-09T12:31:54.371Z",
      "location_count": 107,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03986944"
    },
    {
      "nct_id": "NCT02213029",
      "title": "A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Embryo Transfer"
      ],
      "interventions": [
        {
          "name": "Epelsiban",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Oxytocin",
          "type": "DRUG"
        },
        {
          "name": "Ortho-Cylcen (21)® tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 33,
      "start_date": "2014-08-28",
      "completion_date": "2016-02-07",
      "has_results": false,
      "last_update_posted_date": "2017-05-08",
      "last_synced_at": "2026-09-09T12:31:54.371Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02213029"
    },
    {
      "nct_id": "NCT03070951",
      "title": "Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uterine Fibroids",
        "Heavy Menstrual Bleeding"
      ],
      "interventions": [
        {
          "name": "OBE2109",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match OBE2109",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match Add-back",
          "type": "DRUG"
        },
        {
          "name": "Add-back",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ObsEva SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 511,
      "start_date": "2017-05-23",
      "completion_date": "2020-10-04",
      "has_results": false,
      "last_update_posted_date": "2021-03-05",
      "last_synced_at": "2026-09-09T12:31:54.371Z",
      "location_count": 23,
      "location_summary": "Chino, California • Huntington Park, California • San Diego, California + 19 more",
      "locations": [
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03070951"
    },
    {
      "nct_id": "NCT04335591",
      "title": "Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "75 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "200 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet to match 75 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet to match 200 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "Add-back capsule (E2 1 mg / NETA 0.5 mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsule to match Add-back capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kissei Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 356,
      "start_date": "2020-03-05",
      "completion_date": "2022-12-15",
      "has_results": true,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-09-09T12:31:54.371Z",
      "location_count": 8,
      "location_summary": "Dothan, Alabama • Homestead, Florida • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Homestead",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Nampa",
          "state": "Idaho"
        },
        {
          "city": "Shawnee Mission",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04335591"
    },
    {
      "nct_id": "NCT03751124",
      "title": "Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uterine Leiomyoma",
        "Uterine Fibroids"
      ],
      "interventions": [
        {
          "name": "Relugolix",
          "type": "DRUG"
        },
        {
          "name": "Estradiol/norethindrone acetate",
          "type": "DRUG"
        },
        {
          "name": "Placebo for relugolix",
          "type": "DRUG"
        },
        {
          "name": "Placebo for E2/NETA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Myovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "51 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 51 Years · Female only"
      },
      "enrollment_count": 229,
      "start_date": "2018-10-16",
      "completion_date": "2021-10-20",
      "has_results": true,
      "last_update_posted_date": "2024-06-25",
      "last_synced_at": "2026-09-09T12:31:54.371Z",
      "location_count": 72,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 61 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03751124"
    },
    {
      "nct_id": "NCT02042196",
      "title": "Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Menopause",
        "Aging"
      ],
      "interventions": [
        {
          "name": "KUVAN",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Cetrotide",
          "type": "DRUG"
        },
        {
          "name": "Climara",
          "type": "DRUG"
        },
        {
          "name": "Placebo transdermal patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 70 Years · Female only"
      },
      "enrollment_count": 100,
      "start_date": "2013-12",
      "completion_date": "2016-05-02",
      "has_results": false,
      "last_update_posted_date": "2019-07-11",
      "last_synced_at": "2026-09-09T12:31:54.371Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02042196"
    },
    {
      "nct_id": "NCT03992846",
      "title": "Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "75 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "200 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "Add-back capsule (E2 1 mg / NETA 0.5 mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet to match 75 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet to match 200 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsule to match Add-back capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kissei Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 486,
      "start_date": "2019-06-13",
      "completion_date": "2022-04-01",
      "has_results": true,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-09-09T12:31:54.371Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Chiefland, Florida + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Chiefland",
          "state": "Florida"
        },
        {
          "city": "Homestead",
          "state": "Florida"
        },
        {
          "city": "Lake City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03992846"
    },
    {
      "nct_id": "NCT04372121",
      "title": "Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "75 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "200 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "Add-back capsule (E2 1 mg / NETA 0.5 mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet to match 75 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet to match 200 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsule to match Add-back capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kissei Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2020-03-23",
      "completion_date": "2021-02-16",
      "has_results": true,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-09-09T12:31:54.371Z",
      "location_count": 23,
      "location_summary": "Little Rock, Arkansas • Norwalk, California • Greenwood Village, Colorado + 17 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Norwalk",
          "state": "California"
        },
        {
          "city": "Greenwood Village",
          "state": "Colorado"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04372121"
    }
  ]
}